Fosun Pharma Subsidiary Signs Licensing Agreement with Eisai for Serplulimab Injection in Japan

Fosun PharmaceuticalAnnouncement: Shanghai Henlius Biotech, Inc., a controlled subsidiary of the Company, has entered into a "License Agreement" with Eisai. Under the agreement, Eisai is granted rights to develop, manufacture, and commercialize Serplulimab Injection within the licensed territory (i.e., Japan) and field (i.e., for oncology indications). According to the terms, Eisai shall pay Shanghai Henlius Biotech, Inc. an upfront non-refundable payment and regulatory milestone payments of up to 155 million US dollars for the licensed product. Based on the annual net sales of the licensed product in the licensed territory, Eisai shall make sales milestone payments of up to 233 million US dollars to Shanghai Henlius Biotech, Inc. Fosun Pharmaceutical announced on the same day that the marketing application for Fumaning® (generic name: Luvoxamine Methylate Tablets), independently developed by its controlled subsidiary Fosun Pharmaceutical Industry for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with Type I neurofibromatosis (NF1), was accepted by the National Medical Products Administration (NMPA) and included in the priority review process. Additionally, the drug registration application for Cyclophosphamide Injection from the controlled subsidiary Fresenius Kabi AG (Wuhan) was also accepted by the NMPA.

(This article is from Yicai)